Circulating tumor cell isolation and diagnostics: toward routine clinical use

A. Stolpe, van de; K. Pantel; S. Sleijfer; L.W. Terstappen; J.M.J. Toonder, den

doi:10.1158/0008-5472.CAN-11-1254

Circulating tumor cell isolation and diagnostics: toward routine clinical use

A. Stolpe, van de, K. Pantel, S. Sleijfer, L.W. Terstappen, J.M.J. Toonder, den

Onderzoeksoutput: Bijdrage aan tijdschrift › Tijdschriftartikel › Academic › peer review

170 Citaten (Scopus)

Samenvatting

From February 7–11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type–specific isolation technologies, as well as complex clinical interpretation software, are required. Cancer Res; 71(18); 5955–60. ©2011 AACR.

Originele taal-2	Engels
Pagina's (van-tot)	5955-5960
Tijdschrift	Cancer Research
Volume	71
Nummer van het tijdschrift	18
DOI's	https://doi.org/10.1158/0008-5472.CAN-11-1254
Status	Gepubliceerd - 13 sep. 2011

Duurzame ontwikkelingsdoelstellingen van de VN

Deze output draagt bij aan de volgende duurzame ontwikkelingsdoelstelling(en)

Toegang tot document

10.1158/0008-5472.CAN-11-1254

Citeer dit

@article{22596153e19d45a1aaad7c47b00d89ff,

title = "Circulating tumor cell isolation and diagnostics: toward routine clinical use",

abstract = "From February 7–11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as {"}liquid biopsy{"} from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type–specific isolation technologies, as well as complex clinical interpretation software, are required. Cancer Res; 71(18); 5955–60. {\textcopyright}2011 AACR.",

author = "{Stolpe, van de}, A. and K. Pantel and S. Sleijfer and L.W. Terstappen and {Toonder, den}, J.M.J.",

year = "2011",

month = sep,

day = "13",

doi = "10.1158/0008-5472.CAN-11-1254",

language = "English",

volume = "71",

pages = "5955--5960",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Circulating tumor cell isolation and diagnostics: toward routine clinical use

AU - Stolpe, van de, A.

AU - Pantel, K.

AU - Sleijfer, S.

AU - Terstappen, L.W.

AU - Toonder, den, J.M.J.

PY - 2011/9/13

Y1 - 2011/9/13

N2 - From February 7–11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type–specific isolation technologies, as well as complex clinical interpretation software, are required. Cancer Res; 71(18); 5955–60. ©2011 AACR.

AB - From February 7–11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type–specific isolation technologies, as well as complex clinical interpretation software, are required. Cancer Res; 71(18); 5955–60. ©2011 AACR.

U2 - 10.1158/0008-5472.CAN-11-1254

DO - 10.1158/0008-5472.CAN-11-1254

M3 - Article

C2 - 21896640

SN - 0008-5472

VL - 71

SP - 5955

EP - 5960

JO - Cancer Research

JF - Cancer Research

IS - 18

ER -

Circulating tumor cell isolation and diagnostics: toward routine clinical use

Samenvatting

Duurzame ontwikkelingsdoelstellingen van de VN

Toegang tot document

Vingerafdruk

Citeer dit